CGON
CG Oncology, Inc. Common stock
There isn't enough reported data to score CGON yet.
CGON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CGON's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CGON PE Valuation
CGON has no meaningful PE right now: it lost money over the past year.
CGON Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CGON's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CGON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.77 | -$0.74 |
| Q2 2026 | -$2.70 | -$0.94 |
| Q1 2026 | -$2.34 | -$0.84 |
| Q4 2025 | -$2.08 | -$0.67 |
| Q3 2025 | -$2.03 | -$0.76 |
| Q2 2025 | -$1.76 | -$0.51 |
| Q1 2025 | -$1.50 | -$0.36 |
| Q4 2024 | -$1.41 | -$0.50 |
CGON lost $2.77 per share over the past year, a bigger loss than the year before.
CGON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -3.7% |
| Q1 2026 | $1.1M | +1983% |
| Q4 2025 | $2.3M | +409% |
| Q3 2025 | $1.7M | +3774% |
| Q1 2025 | $52K | -90% |
| Q4 2024 | $456K | +45500% |
| Q3 2024 | $43K | +378% |
| Q1 2024 | $529K | +173% |
CGON's revenue is growing: $2M last quarter, down 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3943% | -874 points |
| Q2 2026 | -7468% | N/A |
| Q1 2026 | -6130% | +75031 points |
| Q4 2025 | -2097% | +6247 points |
| Q3 2025 | -3069% | +62733 points |
| Q1 2025 | -81162% | -76914 points |
| Q4 2024 | -8344% | +1884856 points |
| Q3 2024 | -65802% | +90231 points |
CGON's operating margin was −3943% last quarter, down 874 points from the same quarter a year ago.
CGON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$48.8M | -$9.8M |
| Q2 2026 | -$46.9M | -$18.9M |
| Q1 2026 | -$57.2M | -$28M |
| Q4 2025 | -$36.2M | -$15.4M |
| Q3 2025 | -$39M | -$23.1M |
| Q2 2025 | -$28M | -$11.8M |
| Q1 2025 | -$29.3M | -$3.3M |
| Q4 2024 | -$20.9M | -$4.8M |
CGON has burned cash in almost every quarter: −$189M over the past year, against −$117M the year before.
CGON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +671K shares |
| 1 year | +16% | +12.1M shares |
| 3 years | +33% | +22.2M shares |
CGON has 89M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
CGON Net Leverage
CGON's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CGON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 50.8 | Neutral |
CGON's weekly RSI is 53 (neutral) and its Stochastic is 51 (neutral).
CGON PE vs Healthcare Sector
CGON has no meaningful PE right now: it lost money over the past year.
CGON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.3 | 5.7% above |
| 20 week MA | $70.7 | 0.8% below |
| 50 week MA | $63.2 | 11% above |
| 100 week MA | $46.6 | 51% above |
CGON's trend is mixed: it's above three of its four weekly moving averages, and 51% above its 100-week average.
CGON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $35.0 | $30.0 | -14% |
| 2025 | $30.0 | $39.8 | +33% |
| 2026 YTD | $39.8 | $70.2 | +76% |
CGON is up 76% so far in 2026, after finishing lower in one of the previous two years.